Lenangio 10mg Capsule

• Multiple Myeloma
• Myelodysplastic Syndromes
• Mantle Cell Lymphoma

Like any other anticancer medicine, Lenangio 10mg Capsule   also has some adverse effects on the body, and most of them are manageable without special medical attention.

Some common side effects include:

• Nausea
• Rash
• Headache
• Breathlessness
• Dizziness
• Fatigue
• Decreased white blood cell count (neutrophils)
• Joint pain
• Itching
• Diarrhea
• Low blood platelets
• Peripheral edema
• Cough
• Back pain
• Upper respiratory tract infection
• Decreased appetite
• Nasopharyngitis (inflammation of the throat and nasal passages)

Seek medical attention immediately in case of any severe side effects.

• The dosage of the capsule is usually decided by the doctor as per the patient's health condition, stage & type of cancer. Lenangio 10mg Capsule should be swallowed as a whole with water. It should not be crushed, chewed, or cut.
• In case you experience symptoms of overdose, immediately call your doctor or any other medical emergency helpline.​​
  

• Lenangio 10mg Capsule is an anti-cancer medication. It works by enhancing the immune system's functioning, which indirectly attacks the cancer cells. It prevents the growth of new blood vessels within the tumor.
• It also restricts the production of chemical messengers (cytokines and growth factors), which are responsible for the growth of cancer cells.​​
  

• Chen, N., Zhou, S., & Palmisano, M. (2017). Clinical pharmacokinetics and pharmacodynamics of lenalidomide. Clinical pharmacokinetics, 56(2), 139-152. https://pubmed.ncbi.nlm.nih.gov/27351179/
• McCarthy, P. L., Owzar, K., Hofmeister, C. C., Hurd, D. D., Hassoun, H., Richardson, P. G., ... & Linker, C. (2012). Lenalidomide after stem-cell transplantation for multiple myeloma. New England Journal of Medicine, 366(19), 1770-1781 . https://pubmed.ncbi.nlm.nih.gov/22571201/
• Anderson, K. C. (2005, October). Lenalidomide and thalidomide: mechanisms of action—similarities and differences. In Seminars in Hematology (Vol. 42, pp. S3-S8). WB Saunders. https://pubmed.ncbi.nlm.nih.gov/16344099/
• Armoiry, X., Aulagner, G., & Facon, T. (2008). Lenalidomide in the treatment of multiple myeloma: a review. Journal of clinical pharmacy and therapeutics, 33(3), 219-226. https://pubmed.ncbi.nlm.nih.gov/18452408/
• Fink, E. C., & Ebert, B. L. (2015). The novel mechanism of lenalidomide activity. Blood, The Journal of the American Society of Hematology, 126(21), 2366-2369. https://pubmed.ncbi.nlm.nih.gov/26438514/